Toronto, Canada – Following our recent signing of the Memorandum of Understanding (MOU) between Bruce Power and Kinectrics to collaborate in the production of medical isotopes and to further promote Ontario's role as a world-leader in this innovative field of medical treatment, Kinectrics is pleased to welcome Dr. Travis Besanger, who has accepted the position of Technical and Business Director for Medical Isotopes.
Travis will oversee Kinectrics’ medical isotope business operations working closely with Framatome, who are pioneers in the medical isotope industry, on the integration of their proven target irradiation system into CANDU reactors. Travis will use his knowledge of the radiopharmaceutical industry to build a strong value chain for our products and will also be responsible for establishing a state-of-the-art isotope processing centre at our Teeswater location. Our Teeswater location has the capacity for up to 100,000 sq feet of industrial operations.
As a member of the Kinectrics medical isotopes team, Travis will report to the VP of Radioactive Materials and Chemistry Services, Dr. Amy Gottschling. Dr. Gottschling says “Travis is an entrepreneurial minded individual with the right experience and relationships to take our business plan forward with intensity. It’s an exciting opportunity to significantly increase the availability of therapeutic isotopes, which can be made possible by CANDU reactors like the ones at Bruce Power”.
Travis joins Kinectrics with 13 years of experience in the Radiopharmaceutical Industry. He spent most of his career at the Centre for Probe Development & Commercialization (CPDC), where he led commercialization of radiopharmaceuticals and medical isotope products in his role as Chief Business Officer. During his tenure at CPDC, Travis was responsible for establishing the Glucovision®-FDG network in Ontario, beginning with bringing the operation into GMP compliance, and then structuring sales strategies and partnerships to capture the majority of the regional market share. Most recently, he was appointed President of CPDC’s subsidiary NuGeneris, a privately held subsidiary specializing in late-phase clinical and commercial manufacturing of therapeutic radiopharmaceuticals for international distribution.
About Kinectrics
Kinectrics is the category leader in providing lifecycle management services for the electricity industry. Trusted by clients worldwide, our expertise in engineering, testing, inspection, and certification is backed by our independent laboratory and testing facilities, a diverse fleet of field inspection equipment and an award-winning team of over 1,100 engineers and technicalexperts. From initial design and type testing to operational deployment and maintenance services, Kinectrics collaborates closely with customers to ensure that utility assets perform safely, reliably and efficiently throughout their entire lifecycle. Learn more at www.kinectrics.com and follow us on Twitter, LinkedIn and YouTube.
